Disease · MONDO_0006713

corneal neovascularization

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. corneal neovascularization. Diseases, record MONDO_0006713. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006713

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: corneal neovascularization; Open Targets
Open Targets ID: MONDO_0006713; Open Targets
Other names: Corneal neovascularization (disorder), Corneal neovascularization NOS (disorder), Corneal neovascularization, unspecified, Unspecified corneal neovascularization (disorder); Open Targets
Disease Ontology: DOID:11382; Disease Ontology
MeSH: D016510; MeSH
Highest stage of its drugs: Phase 3, for 1 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	8	8	7	Drugs and targets
RIBOFLAVIN	CHEMBL1534	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 1/2	ClinicalTrials.gov	3	3	2	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
PAZOPANIB	CHEMBL477772	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CONBERCEPT	CHEMBL2108313	Protein	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 1	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	Vascular endothelial growth factor A, long form	4	Vascular endothelial growth factor A inhibitor	Phase 3	https://conductscience.org/library/genes/7422	Drugs and targets
PGF	Placenta growth factor	2	Placenta growth factor inhibitor	Phase 1/2	https://conductscience.org/library/genes/5228	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/1436	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	1	Fibroblast growth factor receptor 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR3	Fibroblast growth factor receptor 3	1	Fibroblast growth factor receptor 3 inhibitor	Phase 1/2	https://conductscience.org/library/genes/2261	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2324	Drugs and targets
ITK	Tyrosine-protein kinase ITK/TSK	1	Tyrosine-protein kinase ITK/TSK inhibitor	Phase 1/2	https://conductscience.org/library/genes/3702	Drugs and targets
KDR	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3815	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00512876	Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization	Not applicable	24	2013-07-03	Corneal Neovascularization	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00559936	Topical Avastin for Treatment of Corneal Neovascularization	Phase 1	24	2012-09-24	Corneal Neovascularization	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01257750	Treatment of Corneal Neovascularization With Topical Pazopanib	Phase 1/2	20	2012-11-06	Corneal Neovascularization	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT00681889	Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)	Phase 1	9	2012-11-08	Corneal Neovascularization	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04787471	Corneal Crosslinking for Treatment of Corneal Neovascularization	Phase 2/3	138		Corneal Neovascularization	RIBOFLAVIN	Its record names the disease	ClinicalTrials.gov
NCT04215393	An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization	Phase 1	39		Corneal Neovascularization	CONBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT01501760	Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea	Phase 3	38		Corneal Newvessels	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00555594	Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization	Phase 2/3	18		Corneal Neovascularization	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00681603	Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization	Not applicable	13		Lipid Keratopathy, Penetrating Keratoplasty, Herpetic Keratopathy, Rosacea	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00992849	Bevacizumab for the Treatment of Corneal Neovascularization	Phase 2	10		Corneal Neovascularization	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27124775	RESULT	1	PubMed
27020759	RESULT	1	PubMed
26114826	RESULT	1	PubMed
20136420	RESULT	1	PubMed
19936307	RESULT	1	PubMed
19549103	RESULT	1	PubMed
40172865	DERIVED	1	PubMed
23233252	DERIVED	1	PubMed
22967868	DERIVED	1	PubMed
19365012	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006713

GET https://conductscience.org/api/diseases/v1/MONDO_0006713/drugs

API reference For AI assistants